SOTA/Thematic
Latest evidence on GLP-1s in transplantation
Presenter
Babak Orandi (US)
Obesity Management in Transplantation: Current Evidence and Practical Approaches Click to watch
Babak Orandi (Guest Speaker)
In this episode of Behind the Paper, Macey Levan, Social Media Editor for the Transplantation journals, speaks with Babak J. Orandi, MD, about the article. Babak J. Orandi will be presenting this work at TTS 2026.
Antiobesity Interventions in Living Organ Donor Candidates: Ethical and Policy Considerations
The discussion focuses on the ethical and policy questions raised by antiobesity interventions for living organ donor candidates. Dr. Orandi explains how obesity can affect donor eligibility and why weight management should be approached as long-term care rather than simply meeting a temporary BMI threshold to enable donation.
The episode explores the four major principles of bioethics — autonomy, beneficence, non-maleficence, and justice — and how they apply to living donor evaluation. Dr. Orandi also discusses the growing role of GLP-1 medications, access to treatment, donor safety, and legal and ethical concerns related to funding weight-loss interventions before donation.
The conversation highlights the importance of sustainable obesity management, better long-term follow-up data, and updated guidance from transplant societies as antiobesity therapies become more widely used.
Antiobesity Interventions in Living Organ Donor Candidates: Ethical and Policy Considerations
The discussion focuses on the ethical and policy questions raised by antiobesity interventions for living organ donor candidates. Dr. Orandi explains how obesity can affect donor eligibility and why weight management should be approached as long-term care rather than simply meeting a temporary BMI threshold to enable donation.
The episode explores the four major principles of bioethics — autonomy, beneficence, non-maleficence, and justice — and how they apply to living donor evaluation. Dr. Orandi also discusses the growing role of GLP-1 medications, access to treatment, donor safety, and legal and ethical concerns related to funding weight-loss interventions before donation.
The conversation highlights the importance of sustainable obesity management, better long-term follow-up data, and updated guidance from transplant societies as antiobesity therapies become more widely used.